bispesifisissä
Bispesifisissä refers to a specific type of drug designed to target two distinct biological entities simultaneously. This dual-action approach is a key characteristic of bispecific antibodies, a class of engineered proteins that have gained significant attention in the field of medicine, particularly in oncology. These molecules are constructed to possess two separate binding sites, each capable of recognizing and attaching to a different target. For instance, one binding site might be designed to engage with a specific protein on a cancer cell, while the other site could bind to a molecule that activates immune cells, such as a T-cell receptor.
The therapeutic mechanism of bispesifisissä drugs typically involves bringing the two targeted entities into close proximity.
The development of bispesifisissä drugs represents a significant advancement in precision medicine. Their ability to engage